Pretty happy. Not a lot to go on just yet as we will get more info in the half yearly.
Wonderful to see our cash balance more than double in the quarter to $1.5 million on ZinClear sales alone. The R&D credit will further bolster cash levels next quarter so we should maintain and continue to grow a strong war chest of cash - >$2-2.5m+ is easily achieveable.
Based on their growth on prior corresponding half we can expect ZinClear revenue to be about $2.25 million for the current half - which is more than the entire total revenue for 1H16! Just incredible. As forecasted, we are on target to hit ~$5m ZinClear sales for the full year as we continue to grow at these double digit rates.
Once we add in the Merck revenue in 2H17, we should end the year in a very strong cash and profit position - a nice dividend is almost a given.
It is a GREAT time to be a shareholder. Congratulations to those who got in today prior to the release - couldn't have timed it better.
![]()
- Forums
- ASX - By Stock
- ANO
- Ann: Appendix 4C - quarterly
ANO
advance zinctek limited
Add to My Watchlist
0.00%
!
78.0¢

Ann: Appendix 4C - quarterly, page-3
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
78.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $48.86M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1922 | 78.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
79.0¢ | 6999 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1922 | 0.780 |
1 | 825 | 0.775 |
2 | 26835 | 0.770 |
1 | 1371 | 0.725 |
2 | 62274 | 0.720 |
Price($) | Vol. | No. |
---|---|---|
0.790 | 6999 | 1 |
0.800 | 5994 | 2 |
0.820 | 7363 | 1 |
0.000 | 0 | 0 |
0.000 | 0 | 0 |
Last trade - 16.21pm 04/07/2025 (20 minute delay) ? |
Featured News
ANO (ASX) Chart |
Day chart unavailable
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
SPONSORED BY The Market Online